Literature DB >> 24417697

κ Opioid receptor ligands regulate angiogenesis in development and in tumours.

Kohei Yamamizu1, Yusuke Hamada, Minoru Narita.   

Abstract

UNLABELLED: Opioid systems mainly regulate physiological functions such as pain, emotional tone and reward circuitry in neural tissues (brain and spinal cord). These systems are also found in extraneural tissues (ganglia, gut, spleen, stomach, lung, pancreas, liver, heart, blood and blood vessels), and recent studies have elucidated their roles in various organs. The current review focuses on the roles of opioid systems in blood vessels, especially angiogenesis, during development and tumour malignancy. The balance between endogenous activators and inhibitors of angiogenesis delicately maintains a normally quiescent vasculature to sustain homeostasis. Disturbance of this balance causes pathogenic angiogenesis and, especially in tumours, several activators such as VEGF are highly expressed in the tumour microenvironment and strongly induce tumour angiogenesis, the so-called angiogenic switch. Recently, we demonstrated that κ opioid receptor agonists function as anti-angiogenic factors, which impede the angiogenic switch, in vascular development and tumour angiogenesis by inhibiting the expression of receptors for VEGF. In clinical medicine, angiogenesis inhibitors that target VEGF signalling such as bevacizumab are used as anti-cancer drugs. Although therapies that inhibit tumour angiogenesis have been highly successful for tumour therapy, most patients eventually develop resistance to this anti-angiogenic therapy. Thus, we must identify novel targets for anti-angiogenic agents to sustain inhibition of angiogenesis for tumour therapy. The regulation of responses to κ opioid receptor ligands could be useful for controlling vascular formation under physiological conditions and in cancers, and thus could offer therapeutic benefits beyond the relief of pain. LINKED ARTICLES: This article is part of a themed section on Opioids: New Pathways to Functional Selectivity. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2015.172.issue-2.
© 2014 The British Pharmacological Society.

Entities:  

Keywords:  angiogenesis; cancer therapy; embryonic stem cells; endothelial cells; opioid; tumour

Mesh:

Substances:

Year:  2014        PMID: 24417697      PMCID: PMC4292944          DOI: 10.1111/bph.12573

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  58 in total

1.  Ontogeny of the opioid growth factor, [Met5]-enkephalin, preproenkephalin gene expression, and the zeta opioid receptor in the developing and adult aorta of rat.

Authors:  Y Wu; P J McLaughlin; I S Zagon
Journal:  Dev Dyn       Date:  1998-04       Impact factor: 3.780

Review 2.  Exploring the opioid system by gene knockout.

Authors:  Brigitte L Kieffer; Claire Gavériaux-Ruff
Journal:  Prog Neurobiol       Date:  2002-04       Impact factor: 11.685

3.  Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor.

Authors:  S Soker; S Takashima; H Q Miao; G Neufeld; M Klagsbrun
Journal:  Cell       Date:  1998-03-20       Impact factor: 41.582

4.  High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis.

Authors:  B Millauer; S Wizigmann-Voos; H Schnürch; R Martinez; N P Møller; W Risau; A Ullrich
Journal:  Cell       Date:  1993-03-26       Impact factor: 41.582

5.  Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium.

Authors:  G H Fong; J Rossant; M Gertsenstein; M L Breitman
Journal:  Nature       Date:  1995-07-06       Impact factor: 49.962

6.  Synergistic effects of methylnaltrexone with 5-fluorouracil and bevacizumab on inhibition of vascular endothelial growth factor-induced angiogenesis.

Authors:  Patrick A Singleton; Joe G N Garcia; Jonathan Moss
Journal:  Mol Cancer Ther       Date:  2008-06       Impact factor: 6.261

7.  Effect of repeated administration of TRK-820, a kappa-opioid receptor agonist, on tolerance to its antinociceptive and sedative actions.

Authors:  Tomohiko Suzuki; Naoki Izumimoto; Yuko Takezawa; Morihiro Fujimura; Yuko Togashi; Hiroshi Nagase; Toshiaki Tanaka; Takashi Endoh
Journal:  Brain Res       Date:  2004-01-09       Impact factor: 3.252

8.  Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth.

Authors:  Kalpna Gupta; Smita Kshirsagar; Liming Chang; Robert Schwartz; Ping-Y Law; Doug Yee; Robert P Hebbel
Journal:  Cancer Res       Date:  2002-08-01       Impact factor: 12.701

9.  Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.

Authors:  Dan Huang; Yan Ding; Yan Li; Wang-Mei Luo; Zhong-Fa Zhang; John Snider; Kristin Vandenbeldt; Chao-Nan Qian; Bin Tean Teh
Journal:  Cancer Res       Date:  2010-01-26       Impact factor: 12.701

10.  Embryonic development is disrupted by modest increases in vascular endothelial growth factor gene expression.

Authors:  L Miquerol; B L Langille; A Nagy
Journal:  Development       Date:  2000-09       Impact factor: 6.868

View more
  19 in total

1.  Themed section.

Authors:  M J Christie; M Connor; J R Traynor
Journal:  Br J Pharmacol       Date:  2015-01       Impact factor: 8.739

2.  Analysis of the Immunoexpression of Opioid Receptors and their Correlation with Markers of Angiogenesis, Cell Proliferation and Apoptosis in Breast Cancer.

Authors:  Alceu Machado De Sousa; Thinali Sousa Dantas; Paulo Goberlânio De Barros Silva; Conceição Da Silva Martins; Gildenio Estevam Freire; Howard Lopes Ribeiro Junior; Gerly Anne De Castro Brito; Karuza Maria Alves Pereira; Renata Ferreira De Carvalho Leitão
Journal:  Asian Pac J Cancer Prev       Date:  2021-02-01

3.  Morphine promotes angiogenesis by activating PI3K/Akt/HIF-1α pathway and upregulating VEGF in hepatocellular carcinoma.

Authors:  Zhiyao Wang; Linghui Jiang; Jie Wang; Zongtao Chai; Wanxia Xiong
Journal:  J Gastrointest Oncol       Date:  2021-08

4.  Generation of a KOR-Cre knockin mouse strain to study cells involved in kappa opioid signaling.

Authors:  Xiaoyun Cai; Huizhen Huang; Marissa S Kuzirian; Lindsey M Snyder; Megumi Matsushita; Michael C Lee; Carolyn Ferguson; Gregg E Homanics; Alison L Barth; Sarah E Ross
Journal:  Genesis       Date:  2015-12-18       Impact factor: 2.487

5.  Androgen represses opioid growth factor receptor (OGFR) in human prostate cancer LNCaP cells and OGFR expression in human prostate cancer tissue.

Authors:  Hironobu Yamashita; Lauren Shuman; Joshua I Warrick; Jay D Raman; David J Degraff
Journal:  Am J Clin Exp Urol       Date:  2018-08-20

Review 6.  FGFs: crucial factors that regulate tumour initiation and progression.

Authors:  Qian Jing; Yuanyuan Wang; Hao Liu; Xiaowei Deng; Lin Jiang; Rui Liu; Haixing Song; Jingyi Li
Journal:  Cell Prolif       Date:  2016-07-07       Impact factor: 6.831

Review 7.  The Relationship Between Regional Anesthesia and Cancer: A Metaanalysis.

Authors:  Ravi K Grandhi; Samuel Lee; Alaa Abd-Elsayed
Journal:  Ochsner J       Date:  2017

8.  Opioid System Modulates the Immune Function: A Review.

Authors:  Xuan Liang; Renyu Liu; Chunhua Chen; Fang Ji; Tianzuo Li
Journal:  Transl Perioper Pain Med       Date:  2016

9.  Mechanism Governing Human Kappa-Opioid Receptor Expression under Desferrioxamine-Induced Hypoxic Mimic Condition in Neuronal NMB Cells.

Authors:  Jennifer Babcock; Alberto Herrera; George Coricor; Christopher Karch; Alexander H Liu; Aida Rivera-Gines; Jane L Ko
Journal:  Int J Mol Sci       Date:  2017-01-20       Impact factor: 5.923

10.  Down-regulation of the tumour suppressor κ-opioid receptor predicts poor prognosis in hepatocellular carcinoma patients.

Authors:  Dongtai Chen; Yonghua Chen; Yan Yan; Jiahao Pan; Wei Xing; Qiang Li; Weian Zeng
Journal:  BMC Cancer       Date:  2017-08-18       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.